1. Is humoral and cellular response to SARS-CoV-2 vaccine modified by DMT in patients with multiple sclerosis and other autoimmune diseases?
- Author
-
Ana Zabalza, Georgina Arrambide, Susana Otero-Romero, Agustín Pappolla, Paula Tagliani, Samuel López-Maza, Simón Cárdenas-Robledo, Juliana Esperalba, Candela Fernández-Naval, Monica Martínez-Gallo, Mireia Castillo, Mercè Bonastre, Mireia Resina-Salles, Jordina Bertran, Marta Rodriguez-Barranco, Pere Carbonell-Mirabent, Marina Gonzalez, Miguel Merchan, Ana Quiroga-Varela, Albert Miguela, Imma Gómez, Gary Álvarez, René Robles, Dúnia Perez del Campo, Xavier Queralt, Maria José Soler, Irene Agraz, Fernando Martinez-Valle, Breogán Rodríguez-Acevedo, Luciana Midaglia, Ángela Vidal-Jordana, Álvaro Cobo-Calvo, Carmen Tur, Ingrid Galan, Joaquín Castillo, Jordi Río, Carmen Espejo, Manuel Comabella, Carlos Nos, Jaume Sastre-Garriga, Lluís Ramió-Torrentà, Mar Tintoré, and Xavier Montalban
- Subjects
COVID-19 Vaccines ,Multiple Sclerosis ,Neurology ,SARS-CoV-2 ,Vaccination ,COVID-19 ,Humans ,Neurology (clinical) ,Antibodies, Viral - Abstract
Background: The effect of disease-modifying therapies on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine response is unclear. Objectives: We aim to determine the immunological responses to SARS-CoV-2 in multiple sclerosis (MS) and anti-CD20-treated patients with other autoimmune diseases (AID). Methods: Humoral and cellular responses we determined before and 30-90 days after vaccination in patients with MS and anti-CD20-treated patients with other AID in two Catalan centers. Results: 457 patients were enrolled. Findings showed that humoral response decreased under anti-CD20s or sphingosine 1-phosphate receptor modulators (S1PRM) and with longer treatment duration and increased after 4.5 months from the last anti-CD20 infusion. Cellular response decreased in S1PRM-treated. Patients on anti-CD20 can present cellular responses even in the absence of antibodies. Conclusion: Anti-CD20s and S1PRM modify the immunological responses to SARS-CoV-2 vaccines.
- Published
- 2022